Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapport Therapeutics (RAPP) Cash & Equivalents (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Cash & Equivalents data on record, last reported at $476.8 million in Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 727.72% to $476.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $476.8 million, a 727.72% increase, with the full-year FY2025 number at $52.6 million, down 7.32% from a year prior.
  • Cash & Equivalents reached $476.8 million in Q1 2026 per RAPP's latest filing, up from $52.6 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for RAPP hit a ceiling of $476.8 million in Q1 2026 and a floor of $39.3 million in Q3 2024.
  • A 4-year average of $140.7 million and a median of $76.9 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 75.34% in 2024, then skyrocketed 727.72% in 2026.
  • Tracing RAPP's Cash & Equivalents over 4 years: stood at $70.2 million in 2023, then decreased by 19.05% to $56.8 million in 2024, then decreased by 7.32% to $52.6 million in 2025, then soared by 805.69% to $476.8 million in 2026.
  • Business Quant data shows Cash & Equivalents for RAPP at $476.8 million in Q1 2026, $52.6 million in Q4 2025, and $251.4 million in Q3 2025.